The Phase III failure of another novel investigational product for depression, Shire's Vyvanse (lisdexamfetamine dimesylate), is raising questions over the health of the pipeline.
According to BioMedTracker, an affiliate of Scrip, only seven novel drugs have been granted approval for the indication of major...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
